Upload File

fda strengthens warning about sleeping pill dangers...fda said at the time. dr. janet woodcock,...

  • Home
  • Documents
  • FDA strengthens warning about sleeping pill dangers...FDA said at the time. Dr. Janet Woodcock, director of the FDA's Center for Drug Evaluation and Research, said Tuesday that the
1
News Video Traffic Taking Action for You Sports Entertainment Marketplace Don't Waste Your Money Support Site Map Privacy Policy Terms of Use EEO FCC Public Files Public File Contact Scripps TV Station Group © 2019 The E.W. Scripps Co ADVERTISEMENT The #1 Plantar Fasciitis Shoe Shoes with the latest space age materials at unbelievable prices. Free shipping & returns. × ! Watch Local News Florida National Recalls Politics Investigations Driving Tampa Bay Forward Certain commonly used sleeping pills will now contain a new boxed warning alerting patients to possible serious or life-threatening behaviors that may result from taking these drugs, the US Food and Drug Administration announced Tuesday . The move follows several reports of rare but serious injuries and deaths resulting from sleepwalking, sleep- driving and other complex behaviors while sleeping, such as unsafe use of a stove. Eszopiclone (Lunesta), zaleplon (Sonata) and zolpidem (Ambien, Ambien CR, Edluar, Intermezzo and Zolpimist) will require the new boxed warnings, which are the most prominent of FDA cautions, the agency said. "These incidents can occur after the first dose of these sleep medicines or after a longer period of treatment, and can occur in patients without any history of these behaviors and even at the lowest recommended doses," Acting Commissioner Dr. Ned Sharpless said in the statement. The agency also says doctors should not prescribe these medicines to patients who have experienced such episodes after taking these drugs. Millions of Americans use sleeping pills, according to a US Centers for Disease Control and Prevention report : About 4% of adults have used prescription sleep aids in the past month. More adult women (5%) use prescription sleep aids than adult men (3.1%), while white adults (4.7%) are more likely to use the pills than black (2.5%). Not all sleep aids pose these risks, the FDA noted. The labels of sleeping drugs that contain eszopiclone, zaleplon or zolpidem already include a warning, the agency said. Together, the new boxed warning and the new rule against prescribing to at-risk patients are intended to emphasize existing warnings while suggesting that the risk of injury and death is serious. The FDA identified 66 reports of patients over the past 26 years who had taken either eszopiclone, zaleplon or zolpidem and then experienced serious injuries or death while not fully awake. Accidental overdoses, falls, burns, near-drowning, extreme temperature exposures leading to loss of limb, self-inflicted gunshot wounds and suicide attempts were among the 46 non-fatal injuries; 20 deaths occurred due to carbon monoxide poisoning, drowning, falls, hypothermia, car crashes and suicide. "Patients usually did not remember these events," a drug safety communication from the FDA said. "The underlying mechanisms by which these insomnia medicines cause complex sleep behaviors are not completely understood." Pfizer, drug maker of Sonata; Sandoz, maker of Ambien; and Sunovion, maker of Lunesta, did not respond to requests for comment. In 2013, the FDA required makers of sleeping pills with the active ingredient zolpidem to lower their recommended doses . At the time, researchers had found high blood levels of zolpidem in some patients the morning after they took doses affecting their cognitive skills, including their ability to drive. The FDA said then that lower doses of zolpidem would cut down on morning-after blood levels. The agency also noted that the recommended dosages should be lower for women, because they don't process zolpidem out of their systems as quickly as men, though doctors might also consider lowering doses for men. And patients using extended-release forms of these pills are at higher risk of next-morning impairment, according to the agency. All patients should be notified about possible "morning after" risks, the FDA said at the time. Dr. Janet Woodcock, director of the FDA's Center for Drug Evaluation and Research, said Tuesday that the agency has monitored these drugs since they were approved: eszopiclone was approved in 2004, zaleplon in 1999 and zolpidem in 1992. "We'll continue to monitor and evaluate these risks associated with insomnia medications and communicate with the public or consider further actions, as appropriate," she said. Copyright 2019 Cable News Network, Inc., a Time Warner Company. All rights reserved. ADVERTISEMENT NEWS " N AT I O N A L FDA strengthens warning about sleeping pill dangers Posted: 7:12 AM, May 01, 2019 Updated: 7:12 AM, May 01, 2019 By: CNN Newsource ! " # ADVERTISING CURATION BY Coachella herpes spike: Record 250 cases reported per day near festival Sponsored If Your Dog Eats Grass (Do This) Ultimate Pet Nutrition Sponsored Glasses-Wearers Are Going Crazy Over This Website GlassesUSA Blood pressure medication recall expanded due to small amounts of cancer-causing substance HCSO employee arrested for using gift cards meant to aid families in need Sponsored Top Cardiologist: This One Thing Will Properly Flush Out Your Bowels Gundry MD Sponsored US Cardiologist: It's Like a Pressure Wash for Your Insides Health Headlines Sponsored What is Rheumatoid Arthritis? Look For Symptoms, Treatment & More Yahoo! Search Amputee left crawling after scooter batteries confiscated Auditioners give it their all to try and become the next Weeki Wachee Mermaids Making it Easy for You! LOCAL News & Weather on Any Device. ! # $ " % ADVERTISEMENT CLOSE Menu

Upload: others

Post on 03-Jul-2020

1 views

Category:

Documents


0 download

Report

TRANSCRIPT

Page 1: FDA strengthens warning about sleeping pill dangers...FDA said at the time. Dr. Janet Woodcock, director of the FDA's Center for Drug Evaluation and Research, said Tuesday that the

News Video Traffic Taking Action for You Sports Entertainment MarketplaceDon't Waste Your Money Support

Site Map Privacy Policy Terms of Use EEO FCC Public Files Public File ContactScripps TV Station Group© 2019 The E.W. Scripps Co

ADVERTISEMENT

The #1 PlantarFasciitis Shoe

Shoes with the latestspace age materials atunbelievable prices. Freeshipping & returns.

×

! Watch

Local News Florida National Recalls Politics Investigations Driving Tampa Bay Forward

Certain commonly used sleeping pills will now contain a new boxedwarning alerting patients to possible serious or life-threatening behaviorsthat may result from taking these drugs, the US Food and DrugAdministration announced Tuesday . The move follows several reports ofrare but serious injuries and deaths resulting from sleepwalking, sleep-driving and other complex behaviors while sleeping, such as unsafe use ofa stove.

Eszopiclone (Lunesta), zaleplon (Sonata) and zolpidem (Ambien, AmbienCR, Edluar, Intermezzo and Zolpimist) will require the new boxedwarnings, which are the most prominent of FDA cautions, the agency said.

"These incidents can occur after the first dose of these sleep medicines orafter a longer period of treatment, and can occur in patients without anyhistory of these behaviors and even at the lowest recommended doses,"Acting Commissioner Dr. Ned Sharpless said in the statement.

The agency also says doctors should not prescribe these medicines topatients who have experienced such episodes after taking these drugs.

Millions of Americans use sleeping pills, according to a US Centers forDisease Control and Prevention report : About 4% of adults have usedprescription sleep aids in the past month. More adult women (5%) useprescription sleep aids than adult men (3.1%), while white adults (4.7%)are more likely to use the pills than black (2.5%).

Not all sleep aids pose these risks, the FDA noted.

The labels of sleeping drugs that contain eszopiclone, zaleplon orzolpidem already include a warning, the agency said. Together, the newboxed warning and the new rule against prescribing to at-risk patients areintended to emphasize existing warnings while suggesting that the risk ofinjury and death is serious.

The FDA identified 66 reports of patients over the past 26 years who hadtaken either eszopiclone, zaleplon or zolpidem and then experiencedserious injuries or death while not fully awake.

Accidental overdoses, falls, burns, near-drowning, extreme temperatureexposures leading to loss of limb, self-inflicted gunshot wounds andsuicide attempts were among the 46 non-fatal injuries; 20 deathsoccurred due to carbon monoxide poisoning, drowning, falls,hypothermia, car crashes and suicide.

"Patients usually did not remember these events," a drug safetycommunication from the FDA said. "The underlying mechanisms bywhich these insomnia medicines cause complex sleep behaviors are notcompletely understood."

Pfizer, drug maker of Sonata; Sandoz, maker of Ambien; and Sunovion,maker of Lunesta, did not respond to requests for comment.

In 2013, the FDA required makers of sleeping pills with the activeingredient zolpidem to lower their recommended doses . At the time,researchers had found high blood levels of zolpidem in some patients themorning after they took doses affecting their cognitive skills, includingtheir ability to drive.

The FDA said then that lower doses of zolpidem would cut down onmorning-after blood levels. The agency also noted that the recommendeddosages should be lower for women, because they don't process zolpidemout of their systems as quickly as men, though doctors might also considerlowering doses for men. And patients using extended-release forms ofthese pills are at higher risk of next-morning impairment, according to theagency.

All patients should be notified about possible "morning after" risks, theFDA said at the time.

Dr. Janet Woodcock, director of the FDA's Center for Drug Evaluation andResearch, said Tuesday that the agency has monitored these drugs sincethey were approved: eszopiclone was approved in 2004, zaleplon in 1999and zolpidem in 1992. "We'll continue to monitor and evaluate these risksassociated with insomnia medications and communicate with the publicor consider further actions, as appropriate," she said.

Copyright 2019 Cable News Network, Inc., a Time Warner Company. All rights reserved.

ADVERTISEMENT

NEWS " NATIONAL

FDA strengthens warning about sleepingpill dangersPosted: 7:12 AM, May 01, 2019 Updated: 7:12 AM, May 01, 2019

By: CNN Newsource

! " #

ADVERTISING

CURATION BY

Coachella herpes spike: Record 250cases reported per day near festival

Sponsored

If Your Dog Eats Grass (Do This)Ultimate Pet Nutrition

Sponsored

Glasses-Wearers Are Going Crazy OverThis WebsiteGlassesUSA

Blood pressure medication recallexpanded due to small amounts ofcancer-causing substance

HCSO employee arrested for using giftcards meant to aid families in need

Sponsored

Top Cardiologist: This One Thing WillProperly Flush Out Your BowelsGundry MD

Sponsored

US Cardiologist: It's Like a PressureWash for Your InsidesHealth Headlines

Sponsored

What is Rheumatoid Arthritis? LookFor Symptoms, Treatment & MoreYahoo! Search

Amputee left crawling after scooterbatteries confiscated

Auditioners give it their all to try andbecome the next Weeki WacheeMermaids

Making it Easy forYou! LOCAL News &Weather on AnyDevice.

! # $ " %

ADVERTISEMENT

CLOSE

Menu

5/2/19, 7)42 PMPage 1 of 1

Shanghai SUNGO Management Consulting …k183097 - Raymond Luo Page 2 Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made

FDA's Predictive Toxicology Roadmap · FDA’S PREDICTIVE TOXICOLOGY ROADMAP. FDA PREDICTIVE TOXICOLOGY ROADMAP. FDA PREDICTIVE TOXICOLOGY ROADMAP 1 ... product area. In developing

2-Day In-Person Seminar by Ex-FDA Official: FDA's GMP ... › fda-gmp-expectations-phase-i-first-in-ma… · Because a phase 1 clinical trial initially introduces an investigational

Guidance for FDA Review Staff and Sponsors - WR … Documents/CBER-Guid-CMC Review fo… · Guidance for FDA Review Staff and Sponsors ... (HFM-40), 1401 Rockville Pike ... FDA's

Renew food facilities registration, FDA's Global ...36mfjx1a0yt01ki78v3bb46n15gp.wpengine.netdna-cdn.com/wp-content/...Renew food facilities' registration, FDA's Global Initiative,

Update on FDA's Comprehensive Plan for Tobacco and ... · Since 2009, FDA had authority to regulate tobacco products intended for human consumption to reduce harm across the population

energycommerce.house.gov ·  · 2014-04-23The process followed by FDA in proposing this rule appears to stand in stark contrast to ... Director of FDA's Center for Drug Evaluation

FDA's 21 CFR 11 rules

Small Business Guide to FDA€¦ · FDA's role and authority. In 1938, after a toxic elixir killed 107 people, Congress enacted the Food, Drug and Cosmetic Act. Among other provisions,

09-009 - Marchand - FDA's New Initiatives for Patient Safety · • All “disclosables” divested to return to FDA. 2 Learning Objectives 1. Describe FDA’s current and future

AMGEN/media/Supporting Documents/T… · Amgen Inc. is pleased to respond to the FDA's draft guidance documents on the ... 2010 public hearing. Amgen looks forward to ... FDA Biosimilar

FDA's Advice on Slim trim u

Guidance for Industry and FDA Staff · This guidance represents the Food and Drug Administration's (FDA's) current thinking on this topic. It does not create or confer any rights

He Said, She Said: HPV and the FDA - PeaceHealth · 2015. 11. 12. · He Said, She Said: HPV and the FDA Audrey P Garrett, MD, MPH June 6, 2014 . Disclosure • Speaker for Merck

Calen SoutherK193573 - Calen Souther Page 2 Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your

FDA's views on the Diagnostic Accuracy and Innovation Act ... · FDA's views on the Diagnostic Accuracy and Innovation Act (DAIA) ... The FDA supports the goal of legislation to create

GAO-20-572, OVER-THE-COUNTER DRUGS: Information on FDA's … · 2020-07-29 · (OTC) drugs—that is, drugs available without a prescription—through the OTC monograph process. FDA

Fda's warning against sliming diet

FDA's Regulation Of Mobile Health

FDA Consumer, May 1980 · Tuning In on Hearing Aids Hearing losses can be socially, economically, and person ... ported FDA's position prohibiting the marketing of Laetrile, the controversial

Cheryl Wagoner · 2020-06-04 · K200246 - Cheryl Wagoner Page 2 Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a

SGS International Ltd ℅ Daniela LevyK182219 - Daniela Levy Page 2 Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made

GAO-08-835 Prescription Drugs: FDA's Oversight of the ...FDA oversees drug promotion for off-label uses by reviewing promotional materials that drug companies submit to the agency

FDA - New Jersey Institute of Technologyjoelsd/capstone/FDA [Compatibility... · 2015-01-15 · FDA's Mission Statement • “The FDA is responsible for protecting the public health

GHANA FDA AND HARMONIZATION OF MEDICINES ...The FDA's legal mandate is found in part 6 (Tobacco Control Measures), part 7 (organisation and responsibilities of the FDA), and part 8

for GMP of API FDA's Guidelines - Dalton

Re: Docket No. FDA-2018-D-2310: Process to … › sites › default › files › resource › ...Re: Docket No. FDA-2018-D-2310: Process to Request a Review of FDA's Decision Not

Cosmeceuticals or CosmePSEUDOcals: Examining the FDA's Under

DEPARTMENT OF HEALTH AND HUMAN SERVICES Food and … · AERS: FDA's Adverse Event Reporting System; a database of adverse events reported to FDA for drugs and medical devices Acute

Strategies for meeting FDA's UDI Rule

FDA's notification on "Lite fit USA"

FDA's Perspectives on Cross- Contamination in CMO ...c.ymcdn.com/sites/casss.site-ym.com/resource/... · FDA's Perspectives on Cross- Contamination in CMO Facilities, Considering

RA / QA Div. Manager 9F, No. 186 Jian Yi Road Zhonghe District, … · 2 Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has

FDA's warning against asset bold

FDA's warning against la jiao shou shen